Pasithea Therapeutics (KTTA) to Release Quarterly Earnings on Thursday

Posted by on Aug 12th, 2026

Pasithea Therapeutics (NASDAQ:KTTA – Get Free Report) is projected to issue its Q2 2026 results after the market closes on Thursday, August 13th. Analysts expect the company to announce earnings of ($0.16) per share and revenue of $0.30 million for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, August 21, 2026 at 4:00 PM ET.

Pasithea Therapeutics (NASDAQ:KTTA – Get Free Report) last announced its earnings results on Friday, May 15th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.33. On average, analysts expect Pasithea Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Pasithea Therapeutics Stock Performance

Shares of KTTA stock opened at $0.48 on Wednesday. Pasithea Therapeutics has a 1 year low of $0.28 and a 1 year high of $2.06. The stock has a fifty day moving average of $0.51 and a two-hundred day moving average of $0.68. The firm has a market capitalization of $15.94 million, a PE ratio of -0.23 and a beta of 0.29.

Hedge Funds Weigh In On Pasithea Therapeutics

Several hedge funds have recently modified their holdings of KTTA. Squadron Capital Management LLC bought a new position in Pasithea Therapeutics during the fourth quarter valued at about $2,709,000. Janus Henderson Group PLC acquired a new position in Pasithea Therapeutics during the fourth quarter worth about $2,720,000. Adage Capital Partners GP L.L.C. bought a new stake in Pasithea Therapeutics in the fourth quarter worth about $2,709,000. Vivo Capital LLC bought a new stake in Pasithea Therapeutics in the fourth quarter worth about $2,709,000. Finally, Persistent Asset Partners Ltd acquired a new stake in Pasithea Therapeutics in the 4th quarter valued at about $375,000. 23.92% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages recently weighed in on KTTA. HC Wainwright restated a “buy” rating and set a $3.00 price objective on shares of Pasithea Therapeutics in a research note on Tuesday, June 16th. Zacks Research upgraded shares of Pasithea Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 17th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Pasithea Therapeutics in a research note on Wednesday, June 24th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $3.00.

Check Out Our Latest Report on Pasithea Therapeutics

Pasithea Therapeutics Company Profile

(Get Free Report)

Pasithea Therapeutics, Inc (NASDAQ: KTTA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and eventual commercialization of engineered antibody therapeutics for immunological diseases. Leveraging a proprietary discovery engine that integrates advanced computational biology, high-throughput screening and structural analysis, the company aims to identify and generate novel therapeutic molecules that modulate key immune pathways.

The company’s pipeline consists of multiple preclinical and early clinical candidates targeting autoimmune and inflammatory disorders.

Featured Stories

Earnings History for Pasithea Therapeutics (NASDAQ:KTTA)

Receive News & Ratings for Pasithea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pasithea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.